These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37814517)

  • 21. Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes.
    Bergenstal RM; Bode BW; Bhargava A; Wang Q; Knights AW; Chang AM
    Diabetes Ther; 2023 Nov; 14(11):1933-1945. PubMed ID: 37740871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Ultra-Rapid Lispro in Younger and Older Patients with Type 2 Diabetes: Randomized Double-Blind PRONTO-T2D Study.
    Zhang Q; Chigutsa F; Chang AM
    Diabetes Ther; 2022 Aug; 13(8):1547-1557. PubMed ID: 35781789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial.
    Zhou J; Chen S; Cheng J; Zhu J; Lou Y; Bao Y; Jia W
    Sci Bull (Beijing); 2022 Sep; 67(17):1785-1791. PubMed ID: 36546064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study.
    Klaff L; Cao D; Dellva MA; Tobian J; Miura J; Dahl D; Lucas J; Bue-Valleskey J
    Diabetes Obes Metab; 2020 Oct; 22(10):1799-1807. PubMed ID: 32488923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Humalog® 200 U/ml KwikPen™].
    Scheen AJ
    Rev Med Liege; 2015 Oct; 70(10):527-31. PubMed ID: 26727843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial.
    Wadwa RP; Laffel LM; Franco DR; Dellva MA; Knights AW; Pollom RK
    Diabetes Obes Metab; 2023 Jan; 25(1):89-97. PubMed ID: 36054737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites.
    Leohr JK; Dellva MA; LaBell E; Coutant DE; Linnebjerg H
    Clin Ther; 2022 Jun; 44(6):836-847. PubMed ID: 35577602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Efficacy and Safety of Ultra Rapid Lispro in Japanese Patients With Type 1 Diabetes: Subpopulation Analysis of the 52-Week PRONTO-T1D Study.
    Miura J; Nishiyama H; Imori M
    Diabetes Ther; 2021 Sep; 12(9):2471-2484. PubMed ID: 34347267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CamAPS FX Hybrid Closed-Loop with Ultra-Rapid Lispro Compared with Standard Lispro in Adults with Type 1 Diabetes: A Double-Blind, Randomized, Crossover Study.
    Nwokolo M; Lakshman R; Hartnell S; Alwan H; Ware J; Allen JM; Wilinska ME; Evans ML; Hovorka R; Boughton CK
    Diabetes Technol Ther; 2023 Dec; 25(12):856-863. PubMed ID: 37823892
    [No Abstract]   [Full Text] [Related]  

  • 30. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
    Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
    Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ultra-rapid lispro (Lyumjev®)].
    Philips JC; Paquot N
    Rev Med Liege; 2021 Jan; 76(1):64-68. PubMed ID: 33443332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of ultra rapid lispro in the treatment of type 2 diabetes mellitus: a randomized controlled clinical trial].
    Chen S; Zhou J; Lu JY; Bao YQ; Xu JW; Zhu JK; Jia WP
    Zhonghua Nei Ke Za Zhi; 2023 Sep; 62(9):1093-1101. PubMed ID: 37650183
    [No Abstract]   [Full Text] [Related]  

  • 33. Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time.
    Luijf YM; Arnolds S; Avogaro A; Benesch C; Bruttomesso D; Farret A; Heinemann L; Place J; Renard E; Scotton R; DeVries JH;
    Diabetes Technol Ther; 2013 Jul; 15(7):575-9. PubMed ID: 23650901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine-SORELLA 1 Study.
    Garg SK; Wernicke-Panten K; Rojeski M; Pierre S; Kirchhein Y; Jedynasty K
    Diabetes Technol Ther; 2017 Sep; 19(9):516-526. PubMed ID: 28722480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and Depths.
    Ignaut D; Fukuda T; Bandi R; Ermer M; Stoffel MS; Zijlstra E; Paavola C
    J Diabetes Sci Technol; 2024 Jul; 18(4):920-929. PubMed ID: 36326260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects.
    Linnebjerg H; LaBell ES; Dellva MA; Coutant DE; Leohr J
    Diabetes Ther; 2020 Aug; 11(8):1709-1720. PubMed ID: 32535742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.
    Launay B; Zinman B; Tildesley HD; Strack T; Chiasson JL
    Diabetes Care; 1998 Oct; 21(10):1627-31. PubMed ID: 9773721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes.
    Levy CJ; Bailey R; Laffel LM; Forlenza G; DiMeglio LA; Hughes MS; Brown SA; Aleppo G; Bhargava A; Shah VN; Clements MA; Kipnes M; Bruggeman B; Daniels M; Rodriguez H; Calhoun P; Lum JW; Sasson-Katchalski R; Pinsker JE; Pollom R; Beck RW;
    Diabetes Technol Ther; 2024 Sep; 26(9):652-660. PubMed ID: 38696672
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes.
    Garhyan P; Pratt E; Klein O; Famulla S; Zijlstra E; Lalonde A; Swinney M; Kazda C; Dassau E
    J Diabetes Sci Technol; 2023 Mar; 17(2):274-282. PubMed ID: 36575993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.